Comparison
GHRP-6 vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
87616-84-0
910463-68-2
Molecular weight
873.02 g/mol
4113.6 g/mol
Half-life
0.4 h
165 h
Sequence
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
2
3
Effects recorded
4
3
Open conflicts
1
1
Documented adverse events
2
5